echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Global Pharmaceutical CEO Compensation PK: AZ annual salary of 140 million yuan Roche down salary Novar3 sad year-end award

    Global Pharmaceutical CEO Compensation PK: AZ annual salary of 140 million yuan Roche down salary Novar3 sad year-end award

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Earlier this month, AstraZenecom reported its 2020 results, in which it said it would thank CEO Pascal Soriot for winning global recognition for its first decision to develop a vaccine and drug against new coronary pneumonia.
    note that, unlike the "impeachment" of previous years, AstraZeneta's board this year's attitude toward Pascal Soriot is "inspiring leadership".
    let's see how Pascal Soriot's salary is made up? Why did the board give Pascal Soriot, who had been impeached for years, an annual salary increase? What is the annual salary of other MNC CEOs? Pascal Soriot's salary of $21.5 million in 2020 was up 16.2 percent from $18.5 million in 2019 and 45.96 percent from $14.73 million in 2018, or nearly 50 percent over two years, according to drug managers.
    , how does that $21.5 million come about? Pascal Soriot's base salary was $1.79 million in 2019, but the annual bonus was raised to $3.22 million, According to AstraZeneta.
    addition to this, Pascal Soriot will receive equity incentives from 2018.
    its results, AstraZeneta's board also said pascal Soriot's base salary would rise 3 per cent to $1.84 million, in line with the basic wage for all UK workers in 2021.
    , AstraZeneta's board did not express its usual dissatisfaction with Pascal Soriot's pay standards, but instead increased its budget, and the decision in the outbreak gave the board a glimpse of Pascal Soriot's leadership.
    "exceeds its target every three years," AstraZene half said in its earnings report, with a total shareholder return of 77 per cent, well above its European pharmaceutical peers.
    , of course, Pascal Soriot's annual salary is also linked to AstraZeneta's soaring performance.
    2020 results, AstraZene half-year sales rose 9 per cent to $26.617bn, driven mainly by a strong performance of new Chinese medicines in emerging markets.
    China revenue of $5,375 million, or 20.2% of global revenue, and AstraZeneta's highest-selling product worldwide will remain Teresa in 2020, with annual sales of $4.328 billion, up from $4.328 billion 36%; the fastest-growing product was Olapali, with annual sales of $1,776 million, up 48% year-on-year ;PD-L1 also showed strong growth, while Infineon's annual sales were $2,042 million, up 39% year-on-year.
    addition, AstraZenecon's new coronary pneumonia vaccine has been approved in the UK, the European Union and Australia, with total sales of more than $2 million so far.
    's earnings growth, Pascal Soriot also led AstraZeneta's announcement of a $39.4 billion acquisition of Alex Pharmaceuticals at the end of 2020, the largest acquisition in 2020, and is expected to complete 2021Q3, when AstraZeneta will be among the world's MNC TOP10.
    AstraZeneta's previous areas include oncology, cardiovascular and respiratory, and the addition of Alequip Pharmaceuticals will bring strong rare diseases, and it is understood that Alephi Pharmaceuticals has a research and development platform in the field of complementary immunity, with sales of $704 million in 2019, a growth rate of 137 percent, and the platform will produce more products that are expected to grow strongly.
    02 Roche/Novarter CEO's annual salary doubles, a year-end award for the base salary 2020 new crown pandemic raging around the world, seriously affecting global economic growth, most companies are struggling, layoffs and pay cuts.
    even the top CEOs in the pharmaceutical industry have struggled to escape pay cuts, with Severin Schwan, Roche's chief executive, again being cut.
    , who has been CEO of the Roche Group since 2008, is the only executive on the company's executive committee to be awarded a stake, with the rest paid in cash.
    , according to Roche's 2020 annual report, Mr Schwan's total compensation last year was 11.0337 million Swiss francs ($12.2924 million), slightly 4.2 per cent lower than the year before.
    Roche said in its annual report that it had cut the base salary of Severin Schwan's 2020 contract by 500,000 Swiss francs ($560,000) in light of the impact of the new crown pandemic on the economy as a whole.
    , the median compensation package for CEOs of companies with a market capitalisation of more than SFr7.1bn in the pharmaceutical industry is SFr8.1m, and Roche's CEO pay is clearly higher than the industry average.
    also disclosed that Mr Schwan's floating pay, excluding base pay, was actually a slight increase, which is often tied to the company's performance, and that Roche's earnings per share (EPS) had risen 18 per cent a year over the past three years, much to the benefit of shareholders.
    estimates by 19 analysts, Roche expects annual revenue growth of 8.2% over the next one to three years.
    2020, Roche's revenues in Swiss franc terms are down 5.3% from the previous year.
    , drug sales fell by 2 per cent, mainly due to bioso-like drugs, particularly in the United States, where the impact of the new crown pandemic led to a decrease in outpatient and hospital admissions.
    specifically, Roche's original "troika" sales declined rapidly, but its ability to build new stars was strong, including the new PD-L1 drug Tecentriq , which also showed strong growth: HER2 A DC's new drug Kadcyla (+34%), Polivy (+248%), and Alecensa (+40%) performed well in all regions, particularly in China, for patients with ALC-NSCLC.
    's chief executive, Vas Narasimhan, also reported a drop in overall compensation of SFr1.1m, or about 10 per cent, compared with 2019.
    Said the decline was mainly due to a reduction in annual bonuses (about SFr700,000), an increase in base pay from March 31, 2020, and no change in the target annual or long-term incentive target (as a percentage of the base annual salary).
    's board of directors awarded the CEO an annual award of 2.6366 million Swiss francs for 2020, which is just the right level (100%) and covers a range of 0% to 200%, or up to twice that.
    LTI programs for 2018-2020 include LTPP (long-term performance plan, weighted by four metrics of compound annual growth in net sales, compound annual growth in core operating income, innovation and total returns relative to shareholders) and LTRPP (long-term relative performance plan).
    last attribution to the LTRPP program is the 2018-2020 cycle, which will cease to be available from 2019.
    According to Novarma Pharmaceuticals, LTPP has achieved impressive results in 2018-2020, with cash value added and innovation exceeding targets, with Novarma ranked 7th in the median return relative to shareholders among 15 global healthcare peers, including Novarma, for 2018-2020 LTRPP.
    overall, when both plans were considered, the board awarded the CEO a total of CHF 8,054.9 million, equivalent to 126 per cent of the expenditure, up to a maximum of 200 per cent.
    From wage-linked earnings, Novart's net sales for the full year 2020 were $48,659 million, compared with 2019, when Novart achieved a 3% growth rate in full-year net sales, its CEO commented.
    Group's global sales continue to be driven by the new psoriasis drug, Courchiyu Monodam, and the heart failure drug Nohintol (Shakuba quartzant sodium tablets).
    year-on-year sales of $3,995 million, up 13 percent year-on-year, while Nohinto rose 44 percent year-on-year to $2.497 billion.
    , Novartic is taking the lead in the results of cell therapy and gene therapy.
    , CAR-T cell therapy Kymriah for blood malignancies was approved by the FDA in 2017 and will grow 42 percent year-on-year to $141 million in 2020. Zolgensma,
    's most expensive new gene therapy drug, has been approved in 37 countries and territories around the world for the treatment of child spinal muscular dystrophy (SMA), driven by European and Japanese reimbursement policies, with full-year sales up 151% year-on-year to $920 million.
    is Novart's best-performing market in the world because of the well-controlled outbreak.
    , Novartra's full-year revenue rose 16 per cent to $2.6bn, and the company's internal assessment is likely to be the second-fastest growing multinational in the country.
    said its goal is to double China's revenues by $2.2bn in 2019 over the next five years.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.